Article Text

Download PDFPDF
CASE REPORT
Missed opportunity for anticoagulation in a patient with AL cardiac amyloidosis and rapidly progressive heart failure
  1. Sindhu Reddy Avula1,
  2. Rishin Handa1,
  3. Bathmapriya Balakrishnan1,
  4. Steven Girard2
  1. 1 Department of Internal Medicine, Saint Joseph Mercy Ann Arbor Hospital, Ypsilanti, Michigan, USA
  2. 2 Department of Cardiovascular Medicine, Saint Joseph Mercy Ann Arbor Hospital, Ypsilanti, Michigan, USA
  1. Correspondence to Dr Sindhu Reddy Avula, sindhu.avula{at}stjoeshealth.org

Summary

A previously healthy 65-year-old woman presented with progressive symptoms of heart failure. Low-voltage ECG and findings on echocardiography were concerning for infiltrative cardiomyopathy. Cardiac MRI showed biventricular late gadolinium enhancement, and endomyocardial biopsy confirmed monoclonal immunoglobulin light-chain (AL) amyloidosis. Bortezomib-based chemotherapy was initiated, but the patient continued to clinically deteriorate. She required hospital readmission after resuscitated out-of-hospital cardiac arrest attributed to progressive conduction disease, and a permanent pacemaker was implanted. Chest CT angiography showed a small subsegmental pulmonary embolism (PE), but anticoagulation was withheld as her lower extremity Doppler was negative. One month later, another pulseless electrical arrest occurred, due to massive PE. Thereafter, she had refractory class IV congestive heart failure with severe right ventricular dysfunction, and was deemed unsuitable for stem-cell or heart transplantation. This case highlights the predilection for thromboembolism in AL cardiac amyloidosis.

  • heart failure
  • cardiovascular medicine
  • haematology (incl blood transfusion)
  • general practice / family medicine

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors Study conception and design: SRA, RH, SG. Data collection: SRA, RH and BB. Data analysis and interpretation: SRA, RH and SG. Drafting the article: SRA, RH and BB. Critical revision of the article: SG, SRA, RH and BB. Final approval of the version to be published: SRA, RH, BB and SG.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.